Intrasense: Confirmation of 2025 Objectives and Strategic Adjustment

Intrasense, a company specializing in medical imaging solutions, confirms its financial targets for 2025 while adjusting its strategy. The company continues to innovate with the Liflow® version 3.x, currently being rolled out, and the DUOnco™ products, which have received CE marking, thus increasing their clinical value in oncology.

The rollout of Liflow® follows a controlled approach with trials in three pilot centers to refine validation before wider commercialization. Concurrently, promising commercial discussions have begun for DUOnco™ Bones and Pancreas.

In response to disappointing results in Italy, Intrasense is pivoting towards AI marketplaces for better market penetration. A cost-cutting plan has also been announced to adjust to slower growth without compromising ongoing operations.

The company is targeting a 2025 turnover of around 3 million euros, representing a growth of 30%, despite cash flow pressures.